Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab, Polatuzumab Vedotin, and Zuberitamab in Newly Diagnosed DLBCL
NCT07231250Phase 2Not yet recruiting
- Start
- Jan 2026
- Primary completion
- Sep 2026
- Modality
- IgG Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab, polatuzumab vedotin, hlx01 in diffuse large B-cell lymphoma (DLBCL). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
glofitamabpolatuzumab vedotinhlx01
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07231250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231250.